Clinical trials of CD47 mAb magrolimab (Hu5F9-G4) as a single agent or in combination for the treatment of relapsed refractory AML have shown promising efficacy (magrolimab, Phase I, ClinicalTrials.gov ID: NCT02678338; magrolimab + atezolizumab, Phase I, ClinicalTrials.gov ID: NCT03922477; magrolimab + azacitidine, Phase Ib, ClinicalTrials.gov ID: NCT03248479). This evidence concerns the gene CD47 and acute myeloid leukemia.